Grant: Project Grant
University of British Columbia
$841,500.00
Targeting Epigenetic Phenotypic Switching to Overcome Prostate Cancer Treatment Resistance
FY 2024-25
Summary
The treatment-induced neuroendocrine prostate cancer (t-NEPC) is a growing subtype of
Prostate cancer and causes more cancer-related death. Treatment for t-NEPC is very limited
as the shortage of knowledge of t-NEPC progression. We have recently found that G9a is
important for t-NEPC progression. In this grant application, we will find out the mechanism by
which G9a drives t-NEPC progression and will design small molecules targeting G9a. We
hope that we will understand more about t-NEPC and develop a treatment.
Department
Program
Project Grant
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
524911
Name
Ong Christopher J
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Cancer Progression & Therapeutics
Projecttitle
Targeting Epigenetic Phenotypic Switching to Overcome Prostate Cancer Treatment Resistance
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$841,500
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Computational Drug Design; Epigenetic Phenotypic Switching; Epigenetic Regulator; Nepc Transdifferentiation
Abstract
The treatment-induced neuroendocrine prostate cancer (t-NEPC) is a growing subtype of
Prostate cancer and causes more cancer-related death. Treatment for t-NEPC is very limited
as the shortage of knowledge of t-NEPC progression. We have recently found that G9a is
important for t-NEPC progression. In this grant application, we will find out the mechanism by
which G9a drives t-NEPC progression and will design small molecules targeting G9a. We
hope that we will understand more about t-NEPC and develop a treatment.
Competitiondate
202503
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Ong, Christopher J
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $841,500~ $0~
